[HTML][HTML] COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
…, A Maynard, A Pawsey, AA Suwaidan, A Okines… - The Lancet …, 2020 - thelancet.com
Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …
[HTML][HTML] Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
[HTML][HTML] Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in …
…, E Hamilton, S Hurvitz, S Loi, A Okines… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor
2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant …
2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant …
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a …
…, D Cunningham, D Gonzalez, AFC Okines… - The lancet …, 2013 - thelancet.com
Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas,
and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR …
and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR …
[HTML][HTML] Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary …
…, SP Stenning, EC Smyth, AF Okines… - The Lancet …, 2017 - thelancet.com
Background Peri-operative chemotherapy and surgery is a standard of care for patients with
resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody …
resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody …
[HTML][HTML] COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
…, N Murugaesu, T Newsom-Davis, AFC Okines… - The Lancet, 2020 - thelancet.com
Background Individuals with cancer, particularly those who are receiving systemic anticancer
treatments, have been postulated to be at increased risk of mortality from COVID-19. This …
treatments, have been postulated to be at increased risk of mortality from COVID-19. This …
[HTML][HTML] Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
…, M O'Brien, K Harrington, S Bhide, A Okines… - Nature cancer, 2021 - nature.com
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy …
Importance Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI)
are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early …
are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early …
[HTML][HTML] Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial
…, D Cunningham, WH Allum, AFC Okines… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC)
trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a …
trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a …
[HTML][HTML] Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK …
…, HI Grabsch, R Langer, S Pritchard, A Okines… - The lancet …, 2017 - thelancet.com
Background Neoadjuvant chemotherapy before surgery improves survival compared with
surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether …
surgery alone for patients with oesophageal cancer. The OE05 trial assessed whether …